Menu

Bausch + Lomb Corporation BLCO

Full chart Compare
Set alert

Price alert · BLCO

All alert types
19.99 USD +0.07 (+0.35%)

At closeNov 6, 2026, 4:00 PM EST

19.99 0.00 0.00%

After hours · Nov 6, 4:00 PM ET

19.52 Day range 20.08
14.56 52-week range 20.60
YTD
+17.04%
1 year
+28.72%
Market cap
7.15B
Revenue (ttm)
5.42B
Profit margin
-2.05%
EPS (ttm)
-0.32
Shares out
357.50M
Forward P/E
16.72
YTD return
+17.04%
1-year return
+28.72%
Volume
554.34K
Avg volume
597.28K
Open
19.68
Previous close
19.92
Day's range
19.52 – 20.08
52-week range
14.56 – 20.60
Beta
0.52
Analysts
Buy
Price target
21.71 (+8.6%)
Earnings date
Feb 17, 2027

ALL -0.24 (-1.20%)

15202022202320242025202619.76

Key statistics

Enterprise value
11.77B
PEG ratio
0.89
Price / sales
1.32
Price / book
1.11
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
7.30%
Free cash flow
404.38M
Total cash
513.00M
Total debt
5.10B
Return on equity
-1.58%
Short % of float
5.55%
50-day average
17.58
200-day average
16.73

Financials — quick view

All financials
BLCO Revenue — quarterly 1.38B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
BLCO Net income — quarterly 32.00M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
BLCO EPS — quarterly 0.09
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

BLCO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 17, 2027Dec 30, 20260.36———
Oct 28, 2026Sep 30, 20260.21450.34+0.13+58.51%
Jul 29, 2026Jun 30, 20260.15440.16+0.01+3.63%
Apr 29, 2026Mar 31, 20260.060.08+0.02+33.33%
Feb 18, 2026Dec 31, 20250.350.32-0.03-8.57%
Oct 29, 2025Sep 30, 20250.160.18+0.02+12.50%

Upgrades / downgrades

BLCO analyst upgrades and downgrades
DateFirmActionFromTo
Nov 2, 2026HC Wainwright & Co.downBuyNeutral
Oct 29, 2026JP MorganmainNeutralNeutral
Oct 29, 2026CitigroupmainBuyBuy
Oct 29, 2026RBC CapitalmainOutperformOutperform
Oct 29, 2026Wells FargomainEqual-WeightEqual-Weight
Oct 7, 2026Barclaysinit—Overweight

About Bausch + Lomb Corporation

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
Canada
Website
bausch.com

News

Your note

Sign in to keep a note on BLCO — it syncs with the Stock Master app.

Insider holders

BLCO insider holders
InsiderRelationLatest transactionDateShares held
BAILEY AMBROSE ROBERT DOUGLAS J.D.OfficerStock Award(Grant)Aug 4, 2026264,241
BERNIER NATHALIE DDirectorStock Award(Grant)May 25, 202685,505
BONNEFOY LUCOfficerStock Award(Grant)Aug 4, 2026103,801
ELDESSOUKY OSAMA AChief Financial OfficerStock Award(Grant)Aug 4, 2026393,527
ELDESSOUKY SAMChief Financial OfficerStock Award(Grant)Mar 5, 2026407,130
HASHAD YEHIAOfficerStock Award(Grant)Aug 4, 2026187,350

Institution ownership

BLCO institution ownership
Holder% heldSharesValueReported
Icahn Carl C0.98%3,500,00069.89MJun 29, 2026
Deutsche Bank AG0.96%3,423,04668.36MJun 29, 2026
Oaktree Capital Management LP0.96%3,441,04268.72MJun 29, 2026
Shaw D.E. & Co., Inc.0.93%3,323,02166.36MJun 29, 2026
Davidson Kempner Capital Management LP0.88%3,158,97263.08MJun 29, 2026
Goldentree Asset Management LP0.74%2,660,50853.13MJun 29, 2026

Fund ownership

BLCO fund ownership
Holder% heldSharesValueReported
T. Rowe Price High Yield Fund, Inc.0.23%837,05016.72MAug 30, 2026
TR PRICE-Price (T.Rowe) U.S. High Yield Trust0.13%454,2209.07MJun 29, 2026
T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Dynamic Credit Fd.0.06%204,4914.08MJun 29, 2026
T. ROWE PRICE Inst. INCOME Fd.S, INC.-T. Rowe Price Inst. High Yield F0.06%218,2114.36MAug 30, 2026
Unified Series Trust-BALLAST SMALL/MID CAP ETF0.04%147,8372.95MJun 29, 2026
Gabelli Healthcare & WellnessRx Trust0.04%144,0002.88MSep 29, 2026